Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY) reported its consolidated financial results for the second quarter of FY26, showing healthy growth in revenue and net profit despite a slight decline in EBITDA.
The company posted a net profit of ₹1,347 crore, marking a 7.3% increase compared to ₹1,256 crore in the same period last year. Revenue rose 9.8% to ₹8,828 crore from ₹8,038 crore YoY, reflecting strong demand in both domestic and international markets.
EBITDA for the quarter stood at ₹2,010 crore, down 3.2% from ₹2,076.8 crore in Q2 FY25, while the EBITDA margin contracted to 22.8% from 25.8% last year.
Commenting on the results, Co-Chairman & MD, G V Prasad said: “Growth in Q2 was driven by momentum in branded markets and steady contributions from the Nicotine Replacement Therapy (NRTJ portfolio, which helped offset the decline in U.S. Lenalidomide sales. We remain focused on strengthening our core business, advancing key pipeline assets, driving productivity and Pursuing business development initiatives.”
Disclaimer: This article is for informational purposes only. It is not intended to be investment advice or a recommendation to buy or sell any stock. Readers are advised to consult their financial advisor before making any investment decisions.
